M-Vax + Low-dose Interleukin-2 Versus Placebo Vaccine in Metastatic Melanoma in Patients with Stage IV Melanoma

December 18, 2009

This study will determine whether M-Vax melanoma vaccine is effective in shrinkage of melanomas that have spread (stage IV).

Study Type: Interventional

Age/Sex Requirement: 18 years+ (None)

Sponsor: AVAX Technologies

ClinicalTrials.gov Identifier: NCT00477906

Purpose: Previous studies suggest that the M-Vax melanoma vaccine, which is prepared from patients’ own cancer cells, can stimulated patients' immune system to react against their cancer. AVAX has identified a dose and schedule of administration of M-Vax that work optimally. This study will determine whether M-Vax is effective in shrinkage of melanomas that have spread (stage IV).

Click here to learn more about the clinical trial.